Inclusion Criteria:

          -  Post-menopausal (if female) defined as: 1) prior bilateral oophorectomy, 2) age 60 or
             over, or 3) < 60 years and amenorrheic for at least 12 months with
             follicle-stimulating hormone (FSH) and estradiol in the postmenopausal range per
             institutional parameters); use of luteinizing hormone-releasing hormone (LHRH)
             agonists to induce chemical ovarian ablation will not be allowed for this study

          -  Tumor is hormone receptor (HR)+ (estrogen receptor and/or progesterone receptor
             positive with at least 10% expression of either receptor by local immunohistochemical
             staining) and HER2 negative based on local assessment

          -  FOR PHASE Ib PORTION OF THE STUDY:

          -  Locally advanced/non-operable or metastatic breast cancer that has not been previously
             treated in the metastatic setting with systemic therapy (i.e. first line treatment)

          -  Measurable disease per RECIST 1.1

          -  FOR PHASE II PORTION OF THE STUDY:

          -  Clinical stage I (breast tumor >= 1.0 cm in diameter), stage II or stage III breast
             cancer (according to the American Joint Committee on Cancer [AJCC] Staging Manual, 7th
             Edition, 2010); multifocal disease is allowed if confined to 1 breast, as long as one
             tumor is at least 1 cm and meets all of the other inclusion criteria

          -  Breast cancer suitable for mandatory baseline core biopsy

          -  No prior systemic therapy or radiotherapy for currently-diagnosed invasive or
             noninvasive breast cancer

          -  FOR ALL PHASES (Ib AND II):

          -  Absolute neutrophil count (ANC) >= 1.5 x 10^9/L

          -  Platelets > 100 x 10^9/L

          -  Hemoglobin >= 8 g/dL (phase Ib) or >= 10 g/dL (for phase II portion)

               -  For phase Ib portion only: patients may receive erythrocyte transfusions to
                  achieve this hemoglobin level at the discretion of the investigator; however,
                  initial study drug treatment must not begin earlier than the day of the
                  erythrocyte transfusion

          -  Bilirubin =< 1.5 times the upper limit of normal (ULN)

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 times ULN

          -  Subjects with Gilbert's syndrome, confirmed by genotyping or Invader UGTIA1 molecular
             assay prior to study entry, must have total bilirubin < 3.0 times ULN

          -  Serum creatinine =< 1.5 times ULN

          -  Lipase =< 1.5 x ULN

          -  International normalized ratio (INR) and partial thromboplastin time (PTT) < 1.5 x ULN

          -  Left ventricular ejection fraction (LVEF) >= 50%

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

        Exclusion Criteria:

          -  FOR PHASE Ib ONLY:

          -  Early stage (curable) breast cancer

          -  FOR PHASE II ONLY:

          -  Metastatic breast cancer (local spread to axillary or internal mammary lymph nodes is
             permitted)

          -  Prior systemic therapy for invasive or non-invasive (DCIS) breast cancer

          -  Prior radiotherapy to the ipsilateral chest wall or breast for any malignancy

          -  Bilateral invasive breast cancer

          -  FOR ALL PHASES (Ib AND II): Inflammatory breast cancer

          -  FOR ALL PHASES (Ib AND II): Concurrent therapy with any other non-protocol anti-cancer
             therapy

          -  FOR ALL PHASES (Ib AND II): History of any other malignancy within the past 5 years,
             with the exception of non-melanoma skin cancer or carcinoma-in-situ of the cervix

          -  FOR ALL PHASES (Ib AND II): Concurrent diagnosis of pheochromocytoma

          -  FOR ALL PHASES (Ib AND II): Current therapy with raloxifene, tamoxifen, aromatase
             inhibitor, or other selective estrogen receptor modulator (SERM), either for
             osteoporosis or prevention of breast cancer; subjects must have discontinued therapies
             for at least 28 days prior to first baseline biopsy

          -  FOR ALL PHASES (Ib AND II): Concurrent treatment with postmenopausal hormone
             replacement therapy; prior treatment must be stopped for at least 28 days prior to
             first baseline biopsy

          -  FOR ALL PHASES (Ib AND II): Type I diabetes or patients on insulin therapy are not
             allowed; uncontrolled type II diabetes not allowed (glycosylated hemoglobin [HbA1c] >
             7.5)

          -  FOR ALL PHASES (Ib AND II): Proteinuria of >= Common Terminology Criteria for Adverse
             Events (CTCAE) grade 3 as estimated by urine protein : creatinine ratio > 3.5 on a
             random urine sample

          -  FOR ALL PHASES (Ib AND II): Uncontrolled arterial hypertension despite optimal medical
             management

          -  FOR ALL PHASES (Ib AND II): Hepatitis B (HBV) or hepatitis C (HCV); all patients must
             be screened for HBV and HCV up to 28 days prior to study drug start using the routine
             hepatitis virus laboratorial panel

          -  FOR ALL PHASES (Ib AND II): Known history of human immunodeficiency virus (HIV)
             infection

          -  FOR ALL PHASES (Ib AND II): Uncontrolled infection; active, clinically serious
             infections (> CTCAE grade 2)

          -  FOR ALL PHASES (Ib AND II): History of significant cardiac disease:

               -  Congestive heart failure > New York Heart Association (NYHA) class 2

               -  Unstable angina (angina symptoms at rest), new-onset angina (begun within the
                  last 3 months)

               -  Myocardial infarction less than 6 months before start of test drug

               -  Anti-arrhythmic therapy (beta blockers or digoxin are permitted)

          -  FOR ALL PHASES (Ib AND II): Arterial or venous thrombotic or embolic events such as
             cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis
             or pulmonary embolism within 3 months before the start of study medication

          -  FOR ALL PHASES (Ib AND II): Participants receiving anticoagulation therapy are not
             allowed

          -  FOR ALL PHASES (Ib AND II): Patients with evidence or history of bleeding diathesis;
             any hemorrhage or bleeding event >= CTCAE grade 3 within 4 weeks of start of study
             medication

          -  FOR ALL PHASES (Ib AND II): Blood or platelet transfusion within 7 days prior to
             treatment start

          -  FOR ALL PHASES (Ib AND II): Non-healing wound or ulcer

          -  FOR ALL PHASES (Ib AND II): History of, or current autoimmune disease

          -  FOR ALL PHASES (Ib AND II): Major surgical procedure or significant traumatic injury
             (as judged by the investigator) within 28 days before start of study medication, open
             biopsy within 7 days before start of study medication

          -  FOR ALL PHASES (Ib AND II): Patients with seizure disorder requiring medication

          -  FOR ALL PHASES (Ib AND II): Known hypersensitivity to any of the study drugs, study
             drug classes, or excipients in the formulation

          -  FOR ALL PHASES (Ib AND II): Systemic continuous corticosteroid therapy at a daily dose
             higher than 15 mg prednisone or equivalent is not allowed; patients may be using
             topical or inhaled corticosteroids; previous corticosteroid therapy must be stopped or
             reduced to the allowed dose at least 7 days prior to the first study drug
             administration; if a patient is on chronic corticosteroid therapy, corticosteroids
             should be de-escalated to the maximum allowed dose after the patient has signed the
             consent document

          -  FOR ALL PHASES (Ib AND II): History of having received an allogeneic bone marrow or
             organ transplant

          -  FOR ALL PHASES (Ib AND II): Chronic oxygen therapy